Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00941798 · ClinicalTrials.gov registry record · Phase 2
Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 2,283
- Enrollment target
NCT00941798: Completed Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT00941798 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,283 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1617% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00941798, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2,283 participants
- Enrollment target
Study Summary
Study CQMF149A2210 evaluated the safety of QMF149 Twisthaler® 500/400 μg, a fixed dose combination of indacaterol 500 μg, a once daily β2 agonist, and mometasone furoate 400 μg, an inhaled corticosteroid (ICS) that is approved for use in the treatment of asthma. The objective of this safety trial was to assess the effect of treatment on the incidence of serious asthma exacerbations, defined as asthma related hospitalization and/or intubation and/or death. This was an event driven trial.
Primary Outcome
Defined as the number of days from start of treatment up to the first date when an asthma exacerbation becomes serious. A serious asthma exacerbation was one that resulted in hospitalization, intubation or death.
Interventions
- DRUG QMF149 Twisthaler®
- DRUG Mometasone Twisthaler®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,283 participants |
| Start Date | 2009-07 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
What the finished NCT00941798 record still lists
NCT00941798 is an interventional study that assigns participants to a tested intervention. Its 2,283 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1617% higher).
The record links to 0 conditions, and to 2 interventions - of which QMF149 Twisthaler® is the first listed.
NCT00941798 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00941798 about?
NCT00941798 is a clinical study titled "Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma". Study CQMF149A2210 evaluated the safety of QMF149 Twisthaler® 500/400 μg, a fixed dose combination of indacaterol 500 μg, a once daily β2 agonist, and mometasone furoate 400 μg, an inhaled corticosteroid (ICS) that is approved for use in the treatment of asthma. The objective of this safety trial wa...
What is the current status of trial NCT00941798?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2,283 participants. The study started on 2009-07. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00941798?
The interventions under investigation include: QMF149 Twisthaler® (DRUG), Mometasone Twisthaler® (DRUG).
Who is sponsoring clinical trial NCT00941798?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00941798's enrollment target sits among peer trials
2,283 8th of 2000 higher than 1,993 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03968393 · 2,270 participants · Phase 4
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
- NCT05530343 · 2,298 participants · NA
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
- NCT04124120 · 2,300 participants · NA
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
- NCT05237258 · 2,300 participants · NA
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia